Pancreatic Cancer Research

ResearcherTohoku UniversityNo recent work listed

Tatsuyuki Takadate

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-6688-3211; OpenAlex author ID A5021174074, A5087688988. Sources: OpenAlex.

Their work

Papers
20 (first author 4, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
50
Papers, trials and grants by year

2011: 1 paper · 2012: none · 2013: 1 paper · 2014: none · 2015: none · 2016: 1 paper · 2017: 4 papers · 2018: 1 paper · 2019: 1 paper · 2020: 3 papers · 2021: 5 papers · 2022: 2 papers · 2023: 1 paper

Papers 20

  1. Expression of Corticotropin-Releasing Hormone and Its Receptors May Be Associated With Survival Rate in Pancreatic Cancer. Co-author DOI 10.1016/j.gastha.2022.09.003↗
  2. Disease-related protein co-expression networks are associated with the prognosis of resectable node-positive pancreatic ductal adenocarcinoma. First author DOI 10.1038/s41598-022-19182-9↗
  3. Impact of Tumor-Derived DNA Testing in Peritoneal Lavage of Pancreatic Cancer Patients with and Without Occult Intra-Abdominal Metastases. Co-author DOI 10.1245/s10434-021-10997-w↗
  4. Circulating tumor DNA as a predictive marker for occult metastases in pancreatic cancer patients with radiographically non-metastatic disease. Co-author DOI 10.1002/jhbp.993↗
  5. Staging laparoscopy is mandatory for the treatment of pancreatic cancer to avoid missing radiologically negative metastases. Co-author DOI 10.1007/s00595-020-02121-4↗
  6. Tolerability of Nab-Paclitaxel Plus Gemcitabine as Adjuvant Setting in Japanese Patients With Resected Pancreatic Cancer: Phase I Study. Co-author DOI 10.1097/mpa.0000000000001702↗
  7. Preceding Systemic Chemotherapy for Patients with Pancreatic Ductal Adenocarcinoma with Positive Peritoneal Cytology Provides Survival Benefit Compared with Up… Co-author DOI 10.1245/s10434-021-09718-0↗
  8. Stomatin‑like protein 2 induces metastasis by regulating the expression of a rate‑limiting enzyme of the hexosamine biosynthetic pathway in pancreatic cancer. Co-author DOI 10.3892/or.2021.8041↗
  9. Prognostic impact of intraoperative peritoneal cytology after neoadjuvant therapy for potentially resectable pancreatic cancer. Co-author DOI 10.1016/j.pan.2020.08.022↗
  10. Stromal expression of hemopexin is associated with lymph-node metastasis in pancreatic ductal adenocarcinoma. First author DOI 10.1371/journal.pone.0235904↗
  11. [A Case of Aortitis Caused by a Granulocyte-Colony-Stimulating Factor during Chemotherapy for Pancreatic Cancer]. First author PMID 32408335↗
  12. [Conversion Surgery for Locally Advanced Unresectable Pancreatic Cancer Treated with FOLFIRINOX Therapy and Proton Beam Therapy Combined with S-1 Chemotherapy-… Co-author PMID 32157015↗
  13. 18-Fluorodeoxyglucose Positron Emission Tomography Predicts Recurrence in Resected Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1007/s11605-017-3627-3↗
  14. Predictive risk factors for peritoneal recurrence after pancreatic cancer resection and strategies for its prevention. Co-author DOI 10.1007/s00595-017-1531-9↗
  15. Locally advanced pancreatic cancer successfully treated by distal pancreatectomy with celiac axis resection (DP-CAR) after S-1 with radiation therapy followed … Co-author DOI 10.1186/s40792-017-0290-6↗
  16. A long-term survival case treated with conversion surgery following chemotherapy after diagnostic metastasectomy for pancreatic cancer with synchronous liver m… Co-author DOI 10.1186/s40792-017-0409-9↗
  17. [Multidisciplinary Therapy with Gemcitabine and Nab-Paclitaxel for Unresectable Pancreatic Cancer]. First author PMID 29394594↗
  18. [A Case of Successful Stomach-Preserving Pancreaticoduodenectomy with Celiac Artery Resection after Neoadjuvant Chemoradiation Therapy for Pancreatic Cancer wi… Co-author PMID 28133191↗
  19. Novel prognostic protein markers of resectable pancreatic cancer identified by coupled shotgun and targeted proteomics using formalin-fixed paraffin-embedded t… Co-author DOI 10.1002/ijc.27797↗
  20. Paclitaxel as second-line chemotherapy in patients with gemcitabine-refractory pancreatic cancer: a retrospective study. Co-author DOI 10.1007/s10147-011-0220-8↗

Closest collaborators

The 25 strongest of 50 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Michiaki Unno · 20 shared papers, 2011–2023 · strength 1.82
  2. Fuyuhiko Motoi · 17 shared papers, 2011–2023 · strength 1.45
  3. Kei Nakagawa · 13 shared papers, 2016–2023 · strength 1.22
  4. Masamichi Mizuma · 14 shared papers, 2016–2022 · strength 1.20
  5. Takanori Morikawa · 13 shared papers, 2011–2022 · strength 1.08
  6. Shimpei Maeda · 12 shared papers, 2011–2022 · strength 0.93
  7. Kyohei Ariake · 9 shared papers, 2017–2021 · strength 0.71
  8. Tatsuo Hata · 7 shared papers, 2017–2022 · strength 0.69
  9. Kei Kawaguchi · 6 shared papers, 2019–2023 · strength 0.67
  10. Masahiro Iseki · 5 shared papers, 2017–2021 · strength 0.45
  11. Shuichi Aoki · 4 shared papers, 2020–2022 · strength 0.45
  12. Takashi Suzuki · 3 shared papers, 2013–2022 · strength 0.28
  13. Yu Katayose · 3 shared papers, 2011–2023 · strength 0.22
  14. Toshihide Nishimura · 2 shared papers, 2013–2022 · strength 0.19
  15. Shinichi Egawa · 4 shared papers, 2011–2017 · strength 0.17
  16. Naoko Sato · 1 shared paper, 2023 · strength 0.17
  17. Mitsuhiro Shimura · 2 shared papers, 2017–2020 · strength 0.14
  18. Kazuharu Chiba · 1 shared paper, 2022 · strength 0.14
  19. Toru Furukawa · 1 shared paper, 2022 · strength 0.14
  20. Kento Miyazaki · 1 shared paper, 2020 · strength 0.13
  21. Katsutaka Mitachi · 1 shared paper, 2021 · strength 0.11
  22. Chao Dang · 1 shared paper, 2021 · strength 0.11
  23. Akira Fukutomi · 1 shared paper, 2021 · strength 0.10
  24. Shoji Nakamori · 1 shared paper, 2021 · strength 0.10
  25. Kumiko Umemoto · 1 shared paper, 2021 · strength 0.10

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.